Cellular signalling pathways: new targets in leukaemia therapy

Br J Haematol. 2002 Jan;116(1):57-77. doi: 10.1046/j.1365-2141.2002.03236.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Cell Line
  • Cytokines / metabolism*
  • DNA-Binding Proteins / antagonists & inhibitors
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • Enzyme Inhibitors / therapeutic use
  • Gene Expression Regulation
  • Humans
  • Interleukins / immunology
  • Interleukins / metabolism
  • Janus Kinase 1
  • Leukemia / drug therapy*
  • Leukemia / immunology
  • Leukemia / metabolism
  • Phosphorylation
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / genetics
  • Protein-Tyrosine Kinases / metabolism
  • Receptor Protein-Tyrosine Kinases / drug effects
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Receptors, Cytokine / metabolism*
  • STAT1 Transcription Factor
  • Signal Transduction / drug effects*
  • Trans-Activators / antagonists & inhibitors
  • Trans-Activators / genetics
  • Trans-Activators / metabolism

Substances

  • Antibodies, Monoclonal
  • Cytokines
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • Interleukins
  • Receptors, Cytokine
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • Trans-Activators
  • Protein-Tyrosine Kinases
  • Receptor Protein-Tyrosine Kinases
  • JAK1 protein, human
  • Janus Kinase 1